English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Support: No funding was received in the publication of this article. Altered neurotransmission of γ-aminobutyric acid (GABA) has been implicated in the pathogenesis of depression. In this expert interview, Dr. Handan Gunduz-Bruce discusses the background and rationale for investigating zuranolone, an oral, positive allosteric modulator of GABA type A (GABAA) receptors, as a potential treatment for postpartum depression and major depressive disorder. She also provides an overview of the clinical programs that will determine zuranolone’s place in the treatment paradigm for these depressive disorders.

us neurology

Zuranolone—An Investigational Oral Neuroactive Steroid and Positive Allosteric Modulator of GABA Type A Receptors for Postpartum Depression and Major Depressive Disorder